<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rfa="http://rfa/20260331"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rfa-20260331.xsd" xlink:type="simple"/>
    <context id="From2025-10-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rfa:UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_OrdinarySharesParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rfa:OrdinarySharesParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_RightsEachRightEntitlingHolderThereofToOnetenthOfOneOrdinaryShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rfa:RightsEachRightEntitlingHolderThereofToOnetenthOfOneOrdinaryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-04-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2026-04-29</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rfa:RedeemableOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rfa:RedeemableOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rfa:NonRedeemableOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">rfa:NonRedeemableOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-02-012026-02-17_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-17_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-17_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember_custom_SponsorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rfa:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember_custom_EarlyBirdCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rfa:EarlyBirdCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_EarlyBirdCapitalIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rfa:EarlyBirdCapitalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_PublicSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rfa:PublicSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_custom_PublicRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rfa:PublicRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-19</endDate>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-09-012025-09-30_custom_FounderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">rfa:FounderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2026-02-19</instant>
        </period>
    </context>
    <context id="AsOf2025-10-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2025-10-09</instant>
        </period>
    </context>
    <context id="From2025-10-012025-10-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-09</endDate>
        </period>
    </context>
    <context id="AsOf2026-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2026-02-17</instant>
        </period>
    </context>
    <context id="From2026-02-012026-02-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_PromissoryNoteRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rfa:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2026-02-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
        </entity>
        <period>
            <instant>2026-02-25</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAOrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">rfa:ClassAOrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-10-012026-03-31_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-02-012026-02-17_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-01</startDate>
            <endDate>2026-02-17</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002091712</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-10-01to2026-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-10-01to2026-03-31" id="Fact000004">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-10-01to2026-03-31" id="Fact000005">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-10-01to2026-03-31" id="Fact000006">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-10-01to2026-03-31" id="Fact000007">0002091712</dei:EntityCentralIndexKey>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0062"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0064"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:DueToSponsor
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:PromissoryNoteRelatedParty
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0085"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:IssuanceOfEbcFounderShares
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0224"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0225"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:IssuanceOfPrivatePlacementUnits
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:IssuanceOfPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0250"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:IssuanceOfPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0255"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:FounderSharesTransferredToThirdpartyDesignees
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:FounderSharesTransferredToThirdpartyDesignees
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0262"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:ForfeitureOfFounderShares
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:ForfeitureOfFounderShares
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0759"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-10-01to2026-03-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-10-01to2026-03-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-10-01to2026-03-31" id="Fact000015">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2025-10-01to2026-03-31" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-10-01to2026-03-31" id="Fact000017">001-43125</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-10-01to2026-03-31" id="Fact000018">RF ACQUISITION CORP III</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-10-01to2026-03-31" id="Fact000019">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-10-01to2026-03-31" id="Fact000020">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-10-01to2026-03-31" id="Fact000021">111 Somerset</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2025-10-01to2026-03-31" id="Fact000022">#05-07</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2025-10-01to2026-03-31" id="Fact000023">Singapore</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2025-10-01to2026-03-31" id="Fact000024">SG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2025-10-01to2026-03-31" id="Fact000025">238164</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-10-01to2026-03-31" id="Fact000026">65</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-10-01to2026-03-31" id="Fact000027">6904 0766</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2025-10-012026-03-31_custom_UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember"
      id="Fact000028">Units, each consisting of one ordinary share and one right to receive one-tenth of one ordinary share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-012026-03-31_custom_UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember"
      id="Fact000029">RFAMU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-012026-03-31_custom_UnitsEachConsistingOfOneOrdinaryShareAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember"
      id="Fact000030">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-10-012026-03-31_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000031">Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-012026-03-31_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000032">RFAM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-012026-03-31_custom_OrdinarySharesParValue0.0001PerShareMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2025-10-012026-03-31_custom_RightsEachRightEntitlingHolderThereofToOnetenthOfOneOrdinaryShareMember"
      id="Fact000034">Rights, each right entitling the holder thereof to one-tenth of one ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2025-10-012026-03-31_custom_RightsEachRightEntitlingHolderThereofToOnetenthOfOneOrdinaryShareMember"
      id="Fact000035">RFAMR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2025-10-012026-03-31_custom_RightsEachRightEntitlingHolderThereofToOnetenthOfOneOrdinaryShareMember"
      id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-10-01to2026-03-31" id="Fact000037">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-10-01to2026-03-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-10-01to2026-03-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-10-01to2026-03-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-10-01to2026-03-31" id="Fact000041">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2025-10-01to2026-03-31" id="Fact000042">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2025-10-01to2026-03-31" id="Fact000043">true</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-04-29"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">13933333</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000052"
      unitRef="USD">933390</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">81353</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">30900</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">1014743</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000059"
      unitRef="USD">30900</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">100403232</us-gaap:AssetsHeldInTrust>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">82594</us-gaap:DeferredOfferingCosts>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">101417975</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">113494</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">24055</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">5658</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000079"
      unitRef="USD">75350</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000080"
      unitRef="USD">57594</us-gaap:OtherAccruedLiabilitiesCurrent>
    <rfa:DueToSponsor
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000082"
      unitRef="USD">16071</rfa:DueToSponsor>
    <rfa:PromissoryNoteRelatedParty
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">41320</rfa:PromissoryNoteRelatedParty>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">115476</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000089"
      unitRef="USD">104572</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">115476</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000092"
      unitRef="USD">104572</us-gaap:Liabilities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000100"
      unitRef="Shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000102"
      unitRef="Shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000104"
      unitRef="USDPShares">10.04</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000106"
      unitRef="USDPShares">0</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000097"
      unitRef="USD">100403232</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000114"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000116"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000118"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000120"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000122"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000124"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000126"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000128"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000133"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000130"
      unitRef="USD">393</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000131"
      unitRef="USD">383</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000149"
      unitRef="USD">241919</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">24617</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000152"
      unitRef="USD">656955</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000153"
      unitRef="USD">-16078</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000155"
      unitRef="USD">899267</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000156"
      unitRef="USD">8922</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000158"
      unitRef="USD">101417975</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000159"
      unitRef="USD">113494</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000162"
      unitRef="USD">99246</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000163"
      unitRef="USD">152199</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000165"
      unitRef="USD">-99246</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000166"
      unitRef="USD">-152199</us-gaap:OperatingIncomeLoss>
    <rfa:ChangeOnFairValueOfOverallotmentLiability
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000171"
      unitRef="USD">422000</rfa:ChangeOnFairValueOfOverallotmentLiability>
    <rfa:ChangeOnFairValueOfOverallotmentLiability
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000172"
      unitRef="USD">422000</rfa:ChangeOnFairValueOfOverallotmentLiability>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000174"
      unitRef="USD">403232</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000175"
      unitRef="USD">403232</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000177"
      unitRef="USD">825232</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000178"
      unitRef="USD">825232</us-gaap:OtherIncome>
    <us-gaap:ProfitLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000180"
      unitRef="USD">725986</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000181"
      unitRef="USD">673033</us-gaap:ProfitLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">4666667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">4666667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">2307692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">2307692</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000191"
      unitRef="USDPShares">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000193"
      unitRef="USDPShares">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000195"
      unitRef="USDPShares">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000197"
      unitRef="USDPShares">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000199"
      unitRef="Shares">3746666</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000201"
      unitRef="Shares">3746666</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">3651740</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">3651740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000206"
      unitRef="USDPShares">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000207"
      unitRef="USDPShares">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000215"
      unitRef="Shares">3833333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000210"
      unitRef="USD">383</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000211"
      unitRef="USD">24617</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000212"
      unitRef="USD">-16078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">8922</us-gaap:StockholdersEquity>
    <rfa:IssuanceOfEbcFounderSharesShares
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000222"
      unitRef="Shares">250000</rfa:IssuanceOfEbcFounderSharesShares>
    <rfa:IssuanceOfEbcFounderShares
      contextRef="From2025-10-012025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000217"
      unitRef="USD">25</rfa:IssuanceOfEbcFounderShares>
    <rfa:IssuanceOfEbcFounderShares
      contextRef="From2025-10-012025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000218"
      unitRef="USD">503105</rfa:IssuanceOfEbcFounderShares>
    <rfa:IssuanceOfEbcFounderShares
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact000220"
      unitRef="USD">503130</rfa:IssuanceOfEbcFounderShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-012025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-52953</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-10-012025-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">-52953</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000234"
      unitRef="Shares">4083333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000229"
      unitRef="USD">408</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000230"
      unitRef="USD">527722</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000231"
      unitRef="USD">-69031</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-12-31"
      decimals="0"
      id="Fact000232"
      unitRef="USD">459099</us-gaap:StockholdersEquity>
    <rfa:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000237"
      unitRef="USD">-5701876</rfa:AccretionOfCarryingValueToRedemptionValue>
    <rfa:AccretionOfCarryingValueToRedemptionValue
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">-5701876</rfa:AccretionOfCarryingValueToRedemptionValue>
    <rfa:IssuancePrivatePlacementShares
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact000246"
      unitRef="Shares">350000</rfa:IssuancePrivatePlacementShares>
    <rfa:IssuanceOfPrivatePlacementUnitsShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000248"
      unitRef="Shares">350000</rfa:IssuanceOfPrivatePlacementUnitsShares>
    <rfa:IssuanceOfPrivatePlacementUnits
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000241"
      unitRef="USD">35</rfa:IssuanceOfPrivatePlacementUnits>
    <rfa:IssuanceOfPrivatePlacementUnits
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000242"
      unitRef="USD">3499965</rfa:IssuanceOfPrivatePlacementUnits>
    <rfa:IssuanceOfPrivatePlacementUnits
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000244"
      unitRef="USD">3500000</rfa:IssuanceOfPrivatePlacementUnits>
    <rfa:IssuanceOfPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000251"
      unitRef="USD">2003000</rfa:IssuanceOfPublicRights>
    <rfa:IssuanceOfPublicRights
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000253"
      unitRef="USD">2003000</rfa:IssuanceOfPublicRights>
    <rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000256"
      unitRef="USD">-1834742</rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights>
    <rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-1834742</rfa:AllocatedValueOfTransactionCostsToPrivatePlacementUnitsAndPublicRights>
    <rfa:FounderSharesTransferredToThirdpartyDesignees
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000261"
      unitRef="USD">1747800</rfa:FounderSharesTransferredToThirdpartyDesignees>
    <rfa:FounderSharesTransferredToThirdpartyDesignees
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">1747800</rfa:FounderSharesTransferredToThirdpartyDesignees>
    <rfa:ForfeitureOfFounderSharesShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000270"
      unitRef="Shares">-500000</rfa:ForfeitureOfFounderSharesShares>
    <rfa:ForfeitureOfFounderShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">-50</rfa:ForfeitureOfFounderShares>
    <rfa:ForfeitureOfFounderShares
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000266"
      unitRef="USD">50</rfa:ForfeitureOfFounderShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000274"
      unitRef="USD">725986</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">725986</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000282"
      unitRef="Shares">3933333</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000277"
      unitRef="USD">393</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000278"
      unitRef="USD">241919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000279"
      unitRef="USD">656955</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000280"
      unitRef="USD">899267</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000287"
      unitRef="USD">673033</us-gaap:ProfitLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000291"
      unitRef="USD">403232</us-gaap:InvestmentIncomeInterest>
    <rfa:ChangeInFairValueOfOverallotmentLiability
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000293"
      unitRef="USD">422000</rfa:ChangeInFairValueOfOverallotmentLiability>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000297"
      unitRef="USD">50453</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <rfa:IncreaseDecreaseInDueToSponsor
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000299"
      unitRef="USD">16071</rfa:IncreaseDecreaseInDueToSponsor>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000301"
      unitRef="USD">18397</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000303"
      unitRef="USD">-168184</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <rfa:InvestmentOfCashIntoTrustAccount
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000307"
      unitRef="USD">100000000</rfa:InvestmentOfCashIntoTrustAccount>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000309"
      unitRef="USD">-100000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000313"
      unitRef="USD">98000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000315"
      unitRef="USD">3500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <rfa:ProceedsFromIssuanceOfEbcFounderShares
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000317"
      unitRef="USD">1630</rfa:ProceedsFromIssuanceOfEbcFounderShares>
    <rfa:ExcessFundsDepositedIntoTrustAccount
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000319"
      unitRef="USD">155913</rfa:ExcessFundsDepositedIntoTrustAccount>
    <rfa:ExcessFundsReturnedToSponsor
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">155913</rfa:ExcessFundsReturnedToSponsor>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000323"
      unitRef="USD">118054</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000325"
      unitRef="USD">159374</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000327"
      unitRef="USD">358736</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000329"
      unitRef="USD">101101574</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000331"
      unitRef="USD">933390</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000335"
      unitRef="USD">933390</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <rfa:DeferredOfferingCostsIncludedInAccruedOfferingCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000339"
      unitRef="USD">75350</rfa:DeferredOfferingCostsIncludedInAccruedOfferingCosts>
    <rfa:FairValueInExcessOfCostsOfEbcFounderShares
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000341"
      unitRef="USD">501500</rfa:FairValueInExcessOfCostsOfEbcFounderShares>
    <rfa:ForfeitureOfFounderShare
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000343"
      unitRef="USD">50</rfa:ForfeitureOfFounderShare>
    <rfa:AccretionOfOrdinarySharesToRedemptionValue
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000345"
      unitRef="USD">5701876</rfa:AccretionOfOrdinarySharesToRedemptionValue>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000347">&lt;p id="xdx_806_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z60XowlHjoZh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 1 &#x2014; &lt;span id="xdx_828_zF73uNZgNF8l"&gt;ORGANIZATION AND BUSINESS OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;RF Acquisition Corp III (the &#x201c;Company&#x201d;) is a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses (a &#x201c;Business Combination&#x201d;). The Company intends to pursue a Business Combination with a target in any industry that can benefit from the expertise and capabilities of the Company&#x2019;s management team. While the Company&#x2019;s efforts in identifying prospective target businesses will not be limited to a particular geographic region, the Company intends to focus its search on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March&#160;31, 2026, the Company had not commenced any operations. All activity for the period from September&#160;15, 2025 (inception) through March&#160;31, 2026 relates to the Company&#x2019;s formation and the initial public offering (the &#x201c;Initial Public Offering&#x201d;), which is described below, and subsequent to the IPO, identifying a target company for a Business. The Company will not generate any operating revenues until after the completion of an initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected September&#160;30 as its fiscal year end.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;30, 2026. On February&#160;17, 2026, the Company consummated the Initial Public Offering of &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zP4Kqsn6QkQb" title="Sale of units in initial public offering"&gt;10,000,000&lt;/span&gt; units (the &#x201c;Units&#x201d; and, with respect to the ordinary shares included in the Units being offered, the &#x201c;Public Shares&#x201d;) at $&lt;span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zjep8FmSzgPk" title="Sale of shares, price per share"&gt;10.00&lt;/span&gt; per Unit, generating gross proceeds of $&lt;span id="xdx_90E_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNfoH3S7zcc2" title="Sale of units in initial public offering aggregate amount"&gt;100,000,000&lt;/span&gt;. Each Unit consists of one Public Share and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial Business Combination (&#x201c;Public Right&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zkLTtlabAEv6" title="Sale of units in initial public offering"&gt;350,000&lt;/span&gt; units (the &#x201c;Private Placement Units&#x201d;) at a price of $&lt;span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zyPGCEJg50r1" title="Sale of shares, price per share"&gt;10.00&lt;/span&gt; per Private Placement Unit, in a private placement to the Company&#x2019;s sponsor, Alfa 30 Limited (the &#x201c;Sponsor&#x201d;) and EarlyBirdCapital, Inc., the representative of the underwriters in the Initial Public Offering (&#x201c;EBC&#x201d;), at a price of $&lt;span id="xdx_902_eus-gaap--SaleOfStockPricePerShare_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zl1vDge77jid" title="Sale of shares, price per share"&gt;10.00&lt;/span&gt; per Private Placement Unit, generating gross proceeds of $&lt;span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zgIsalECB6A7" title="Sale of units in initial public offering aggregate amount"&gt;3,500,000&lt;/span&gt;. Of the &lt;span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zWNlAJXNSwia" title="Sale of units in initial public offering"&gt;350,000&lt;/span&gt; Private Placement Units, the Sponsor and its designees purchased &lt;span id="xdx_905_ecustom--PurchaseOfShares_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zL98ytD2s9Z1" title="Purchase of shares"&gt;250,000&lt;/span&gt; Private Placement Units and EBC purchased &lt;span id="xdx_90D_ecustom--PurchaseOfShares_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zkXI2BUFfF3a" title="Purchase of shares"&gt;100,000&lt;/span&gt; Private Placement Units. Each Private Placement Unit consists of one ordinary share (the &#x201c;Private Shares&#x201d;) and one right to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial Business Combination (&#x201c;Private Placement Right&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transaction costs amounted to $&lt;span id="xdx_903_ecustom--TransactionCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z864L4y7Hc2b" title="Transaction costs"&gt;4,708,386&lt;/span&gt;, consisting of $&lt;span id="xdx_909_eus-gaap--ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_pp0p0_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zsEjQOLApWQl" title="Underwriting fees"&gt;2,000,000&lt;/span&gt; of cash underwriting fee, fair value of EBC founder shares of $&lt;span id="xdx_905_ecustom--FairValueOfFounderShares_c20251001__20260331__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zwNqzHnTdMN5" title="Fair value of founder shares"&gt;501,500&lt;/span&gt;, fair value of Founder Shares transferred to third-party designees of $&lt;span id="xdx_909_ecustom--FairValueOfFounderShares_c20251001__20260331_zb26GnHx0kDh" title="Fair value of founder shares"&gt;1,747,800&lt;/span&gt;, and $&lt;span id="xdx_90B_ecustom--OtherOfferingCosts_pp0p0_c20251001__20260331_zbR5OX2YRAR1" title="Other offering costs"&gt;459,086&lt;/span&gt; of other offering costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. Pursuant to applicable stock exchange listing rules, the Company&#x2019;s initial Business Combination must be with one or more businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (excluding income interest earned on the Trust Account and released to the Company to pay taxes). The Company intends to only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following the closing of the Initial Public Offering, on February&#160;17, 2026, an amount of $&lt;span id="xdx_907_ecustom--ProceedsFromIssuanceInitialPublicOfferings_pp0p0_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zYQFdHPdq1m4" title="Proceeds from Initial Public Offering"&gt;100,000,000&lt;/span&gt; ($&lt;span id="xdx_904_eus-gaap--SharePrice_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z4eN1lOEaUJj" title="Share price"&gt;10.00&lt;/span&gt; per Unit) from the net proceeds of the sale of the Units and the Private Placement Units was placed in the trust account (the &#x201c;Trust Account&#x201d;), located in the United States, with Continental Stock Transfer &amp;amp; Trust Company acting as trustee, and held in demand deposit or cash accounts or invested only in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under Rule&#160;2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company&#x2019;s shareholders, as described below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company will provide the holders of the outstanding Public Shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company in its sole discretion subject to requirements of corporate law. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). The Public Shares subject to possible redemption were recorded at a redemption value and classified as temporary equity at the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board&#x2019;s (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;&lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination only if the Company receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and, subject to applicable securities laws, any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a Business Combination, and irrespective of whether they do not vote or abstain from voting their shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company&#x2019;s prior written consent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;













&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our initial shareholders, including the Sponsor, and EBC have agreed (a) to waive their redemption rights with respect to any Founder Shares, EBC founder shares (as defined in Note 6), Private Shares in connection with the completion of a Business Combination, (b) to waive their redemption rights with respect to their Founder Shares, EBC founder shares and Private Shares in connection with a shareholder vote to approve an amendment to the amended and restated memorandum and articles of association to (1) modify the substance or timing of the obligation to provide for the redemption of the public shares in connection with an initial Business Combination or to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 21 months from the closing of the Initial Public Offering or (2) with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial Business Combination activity, and (c) to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares, EBC founder shares and Private Shares held by them if the Company fails to complete the initial Business Combination within 21 months from the closing of the Initial Public Offering. If the Company submits the initial Business Combination to the public shareholders for a vote, the Sponsor and the Company&#x2019;s officers and directors have agreed (and their permitted transferees will agree) to vote any Founder Shares, Private Shares and, subject to applicable securities laws, any public shares purchased by them in or after this Initial Public Offering (including in open market and privately-negotiated transactions) in favor of an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company will have until 21 months from the closing of the Initial Public Offering to consummate a Business Combination (the &#x201c;Combination Period&#x201d;). However, if the Company has not completed a Business Combination within the Combination Period and the Combination Period is not extended by shareholders pursuant to an amendment to the Company&#x2019;s amended and restated articles of association, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned and not previously released to the Company to pay its taxes, if any (less $&lt;span id="xdx_909_ecustom--DissolutionExpenses_pp0p0_c20251001__20260331_zPe3ZbDsjDKc" title="Dissolution expenses"&gt;100,000&lt;/span&gt; to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to the Founder Shares it would receive if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or any of its affiliates acquires Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $&lt;span id="xdx_90E_ecustom--PublicSharesOutstanding_iI_c20260331_zqbqrYRI32w7" title="Public shares outstanding"&gt;10.00&lt;/span&gt; per Public Share and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $&lt;span id="xdx_908_ecustom--PublicShareDueToReductions_iI_c20260331_zzSPzD9q1py8" title="Public share due to reductions"&gt;10.00&lt;/span&gt; per Public Share, due to reductions in the value of trust assets, in each case net of the interest that may be withdrawn to pay taxes. This liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and as to any claims by the Company&#x2019;s auditors or under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-17_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000351"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_IPOMember"
      decimals="0"
      id="Fact000353"
      unitRef="USD">100000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000355"
      unitRef="Shares">350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000357"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000359"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">3500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember_custom_SponsorMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <rfa:PurchaseOfShares
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000365"
      unitRef="Shares">250000</rfa:PurchaseOfShares>
    <rfa:PurchaseOfShares
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember_custom_EarlyBirdCapitalIncMember"
      decimals="INF"
      id="Fact000367"
      unitRef="Shares">100000</rfa:PurchaseOfShares>
    <rfa:TransactionCosts
      contextRef="From2025-10-012026-03-31_us-gaap_IPOMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">4708386</rfa:TransactionCosts>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="From2025-10-012026-03-31_us-gaap_IPOMember"
      decimals="0"
      id="Fact000371"
      unitRef="USD">2000000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <rfa:FairValueOfFounderShares
      contextRef="From2025-10-012026-03-31_custom_EarlyBirdCapitalIncMember"
      decimals="0"
      id="Fact000373"
      unitRef="USD">501500</rfa:FairValueOfFounderShares>
    <rfa:FairValueOfFounderShares
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000375"
      unitRef="USD">1747800</rfa:FairValueOfFounderShares>
    <rfa:OtherOfferingCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000377"
      unitRef="USD">459086</rfa:OtherOfferingCosts>
    <rfa:ProceedsFromIssuanceInitialPublicOfferings
      contextRef="From2026-02-012026-02-17_us-gaap_IPOMember"
      decimals="0"
      id="Fact000384"
      unitRef="USD">100000000</rfa:ProceedsFromIssuanceInitialPublicOfferings>
    <us-gaap:SharePrice
      contextRef="AsOf2026-02-17_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000386"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <rfa:DissolutionExpenses
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000393"
      unitRef="USD">100000</rfa:DissolutionExpenses>
    <rfa:PublicSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000395"
      unitRef="USDPShares">10.00</rfa:PublicSharesOutstanding>
    <rfa:PublicShareDueToReductions
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000397"
      unitRef="USDPShares">10.00</rfa:PublicShareDueToReductions>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000404">&lt;p id="xdx_800_eus-gaap--SignificantAccountingPoliciesTextBlock_z25SXKv5TkSd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 2 &#x2014; &lt;span id="xdx_822_z04ycRaKxTnd"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUFQAWjMbBqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zwr6lcF7GX7f"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of balance sheets, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s final prospectus in connection with the Company&#x2019;s Current Report on Form 8-K, as filed with the SEC on February&#160;24, 2026. The interim results for the three and six months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the year ending September&#160;30, 2026 or for any future periods. As the Company was incorporated on September&#160;15, 2025 and had no operations prior to that date, there are no corresponding prior-year interim periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zl28Vy1tMTJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_ztBjTfUlQoci"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s liquidity needs prior to the Initial Public Offering had been satisfied through the loan under an unsecured promissory note from the Sponsor of up to $&lt;span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20260331_zOSfH9rrJyF5"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. As of March 31, 2026, the Company had $&lt;span id="xdx_909_eus-gaap--Cash_iI_pp0p0_do_c20260331_zw9b2iX9PMfg"&gt;933,390&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash and working capital surplus of $&lt;span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_zgILkmuj4fi1" title="Working capital deficit"&gt;899,267&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but is not obligated to, loan the Company funds as may be required (the &#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay such loaned amounts at that time. Up to $&lt;span id="xdx_905_eus-gaap--DebtConversionOriginalDebtAmount1_c20251001__20260331_z4du6WD6keXk" title="Conversion of debt"&gt;1,500,000&lt;/span&gt; of such Working Capital Loans may be converted into units upon consummation of the Business Combination at a price of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20260331_zha49kB2Q2Gc" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit. The units would be identical to the Private Placement Units. As of March&#160;31, 2026, the Company had no borrowings under the Working Capital Loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, &#x201c;Presentation of Financial Statements &#x2014; Going Concern,&#x201d; the Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. The Company has the Combination Period to complete the initial Business Combination. Management has determined that the Company has sufficient funds to finance the working capital needs of the Company within one year from the date of issuance of the financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWS7LMpyEH66" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3sCjMk6awYd"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities
Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), and it may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation
requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zgILAhw555Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z76cHeNcThz5"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of this unaudited condensed financial statement in conformity with US GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zkCDlZM9kdaj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zikynz4Ls5ec"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_c20260331_zKFqbklCrEYe" title="Cash"&gt;933,390&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_c20250930_zfYK1oOz1TIh" title="Cash"&gt;0&lt;/span&gt; in cash and &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zecewXHUV8Nj" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250930_zyO1eThGUYIk" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of March 31, 2026 and September 30, 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--CashHeldinTrustAccountPolicyTextBlock_zTFppfFETPT5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zc5hvS4oL489"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of March 31, 2026, the
assets held in the Trust Account, amounting to $&lt;span id="xdx_908_eus-gaap--AssetsHeldInTrust_c20260331_pp0p" title="Cash held in Trust Account"&gt;100,403,232&lt;/span&gt;, were held in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zdlgpl3dm5o2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zZSbCs5fq5Ei"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zGzLNcMYvQa2" title="Federal deposit insurance corporation coverage limit"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_ecustom--DeferredOfferingCostsPolicyTextBlock_zLvheVFDStAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zgmVZZshnAvb"&gt;Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with the requirements of
the FASB ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A, &#x201c;Expenses of Offering&#x201d;. Offering costs consist
principally of professional and registration fees that are related to the Initial Public Offering. Offering costs allocated to the
Public Shares were charged to temporary equity, and offering costs allocated to Public Rights and Private Placement Units were
charged to shareholders&#x2019; equity, as both the Public Rights and Private Placement Rights, after management&#x2019;s evaluation,
were accounted for under equity treatment. Accordingly, $&lt;span id="xdx_90E_ecustom--OfferingCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicSharesMember_zFlu1ZnGHrT1" title="Offering costs"&gt;2,873,644&lt;/span&gt;
was allocated to Public Shares and charged to temporary equity, and $&lt;span id="xdx_900_ecustom--OfferingCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicRightsMember_zlfpAKTETN78" title="Offering costs"&gt;1,834,742&lt;/span&gt;
was allocated to Public Rights and Private Placement Units and charged to shareholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zBymHXdpfR39" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_ze1We6AdDgBe"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;.&#x201d; Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2026 and September 30, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdQ4dtp16ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zHq546xGKkHc"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under FASB ASC 820, &#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt;,&#x201d; approximates the carrying amounts represented in the unaudited condensed balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share Rights&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounted for the Public Rights and Private Placement Rights issued in connection with the Initial Public Offering and the private placement in accordance with the guidance contained in FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d;. Accordingly, the Company evaluated and classified the Share Rights under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIKQ5PfoF7i9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zP1o6qsxnDAj"&gt;Share-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for share awards in accordance with FASB ASC Topic 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (e.g., the occurrence of Initial Public Offering). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zljIzyAqNQng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z0DE5W4ZjSv7"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed balance sheet as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480 since the underwriters did not exercise their overallotment option at the closing of the Initial Public Offering. On February 19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260201__20260219_z5fvzyoJc9Mi" title="Option forfeit"&gt;1,500,000&lt;/span&gt; Units, and the Company derecognized the over-allotment liability accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zYotJdcp1wzf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z9uodEC9C0tj"&gt;Net Income per Ordinary Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The condensed statements of operations include a presentation of income per redeemable share and income per non-redeemable share following the two-class method of income per share. In order to determine the net income attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income allocable to both the redeemable shares and non-redeemable shares and the undistributed income is calculated using the total net income less any dividends paid. The Company then allocated the undistributed income ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The calculation of diluted income per ordinary share does not consider the effect of the rights issued in connection with the Initial Public Offering and the Private Placement Units since the exercise of the units is contingent upon the occurrence of future events. The rights are exercisable to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331_ztF2Gpyl8EWi" title="Shares exercisable"&gt;1,000,000&lt;/span&gt; Ordinary Shares in the aggregate. The &lt;span id="xdx_905_ecustom--OrdinarySharesSubjectToForfeiture_iI_c20260331_zz4M5Jy7brYb" title="Ordinary shares subject to forfeiture"&gt;500,000&lt;/span&gt; ordinary shares that were subject to forfeiture if the over-allotment option was not exercised by the underwriters were not included in the calculation of weighted average shares outstanding. As of March&#160;31, 2026 and September 30, 2025, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares that then share in the earnings of the Company. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Net income per share, basic and diluted, for non-redeemable ordinary shares is calculated by dividing the net loss, adjusted for income attributable to redeemable ordinary shares, by the weighted average number of non-redeemable ordinary shares outstanding for the period. Non-redeemable ordinary shares include the Founder Shares and the Private Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOtTy0GAQmj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B9_z7rBXlhv8M1e" style="display: none"&gt;Basic and diluted net income per ordinary share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260101__20260331_zaoIslaymaof" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20251001__20260331_zp7YkB3eKHJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended &lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;
Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0d_zBehFIO6gTs9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;725,986&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;673,033&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_pp0d_zr9qZUUBOkch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue_pp0d_z6xq6rSiGWlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Net Income including accretion of ordinary shares to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,754&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;269,801&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zihxbn7Z2ET1" title="Net Income"&gt;179,024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zKIgWR5E8hp1" title="Net Income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zruhXWp6Yz2g" title="Net Income"&gt;104,476&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zcr4YQCVWxbd" title="Net Income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zNxLLXI6ish8" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zp7ghk8Yruug" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0502"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_znqDtO0Gv2J9" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zULx6jCSQ6b7" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Allocation of net income&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zTp8r1zueqvg" title="Allocation of net income"&gt;582,256&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zUiLzOHIDxt7" title="Allocation of net income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zLJ7NVAN6Xv2" title="Allocation of net income"&gt;507,708&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zxntwKURzTFf" title="Allocation of net income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zULNoydRXX5" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjJVdeSMPg81" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;4,666,667&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zluo3enOxahd" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zH4MpOBz1KT2" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,746,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zoWPSnJnwshj" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_z0ib8qaoy6Zc" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;2,307,692&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zsXc5y4uESGk" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zmfFwOYx3p8h" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,651,740&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zhyWwQHVrf5j" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zzh4sn32iSue" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjZBfZERHHHa" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_z9trRFdd8iZ7" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A1_zpMNgHheVSpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p id="xdx_84A_ecustom--OrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z5vQwPQ72Rn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zVsNsNlOks2b"&gt;Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote (A) to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Public Shares if the Company does not complete an initial Business Combination within the completion window or (B) with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial Business Combination activity, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available) and accumulated deficit. Accordingly, as of March&#160;31, 2026, the ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s unaudited condensed balance sheet. As of March&#160;31, 2026, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--TemporaryEquityTableTextBlock_zkusVmplSvr8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span id="xdx_8BD_z0KWW4Wlvbii"&gt;&lt;span id="xdx_8B9_zu2jEARQ72Tf" style="display: none"&gt;Schedule of ordinary shares subject to possible redemption&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Gross proceeds&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iS_c20251001__20260331_zx4Yllrgu96k" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OrdinarySharesSubjectToPossibleRedemption_iS_c20251001__20260331_zCP5CPbl6YUa" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to Public Rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ProceedsAllocatedToPublicRights_c20251001__20260331_zXmKL6tlmVL6" style="text-align: right" title="Proceeds allocated to Public Rights"&gt;(2,003,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ProceedsAllocatedToOverallotmentOption_c20251001__20260331_zdMhSa7GLw4h" style="text-align: right" title="Proceeds allocated to over-allotment option"&gt;(422,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary shares issuance cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--PublicSharesIssuanceCosts_c20251001__20260331_zOLe07NOmEj4" style="text-align: right" title="Public Shares issuance costs"&gt;(2,873,644&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20251001__20260331_zqHQeuMRMGJh" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of carrying value to redemption value"&gt;5,701,876&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary Shares subject to possible redemption, March&#160;31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iE_c20251001__20260331_zsmJ2GjBt6ka" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OrdinarySharesSubjectToPossibleRedemption_iE_c20251001__20260331_zqrouuBcG2R5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zIleuDzohXWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5HNLxjIxg1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1H0wFJvopSi"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07,
&#x201c;Segment reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments
in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief
operating decision maker (&#x201c;CODM&#x201d;), as well as the aggregate amount of other segment items included in the reported measure
of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how
the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.
Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with
a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures
in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning
after December&#160;15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 on September 15, 2025, the date of its incorporation.
Please refer to Note 9&#x2014; SEGMENT INFORMATION.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNmoLbdmF7ka" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zrCpBYuN3OU1"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2025, the
FASB issued ASU 2025-11 &#x201c;Interim Reporting (Topic 270): Narrow Scope Improvements (&#x201c;ASU 2025-11&#x201d;), to improve the
guidance for interim reporting and clarify when that guidance is applicable. The ASU 2025-11 provides a comprehensive list of
required disclosures and also requires entities to disclose events since the last annual reporting period that have a material
impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after
December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for
entities other than public business entities. Early adoption is permitted. Management is currently evaluating ASU 2025-11 to determine
its impact on the Company&#x2019;s disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000406">&lt;p id="xdx_846_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zUFQAWjMbBqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zwr6lcF7GX7f"&gt;Basis of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of balance sheets, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the Company&#x2019;s final prospectus in connection with the Company&#x2019;s Current Report on Form 8-K, as filed with the SEC on February&#160;24, 2026. The interim results for the three and six months ended March&#160;31, 2026 are not necessarily indicative of the results to be expected for the year ending September&#160;30, 2026 or for any future periods. As the Company was incorporated on September&#160;15, 2025 and had no operations prior to that date, there are no corresponding prior-year interim periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <rfa:LiquidityAndCapitalResourcesPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000408">&lt;p id="xdx_84F_ecustom--LiquidityAndCapitalResourcesPolicyTextBlock_zl28Vy1tMTJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_ztBjTfUlQoci"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s liquidity needs prior to the Initial Public Offering had been satisfied through the loan under an unsecured promissory note from the Sponsor of up to $&lt;span id="xdx_90E_eus-gaap--UnsecuredDebt_iI_c20260331_zOSfH9rrJyF5"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. As of March 31, 2026, the Company had $&lt;span id="xdx_909_eus-gaap--Cash_iI_pp0p0_do_c20260331_zw9b2iX9PMfg"&gt;933,390&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;cash and working capital surplus of $&lt;span id="xdx_909_ecustom--WorkingCapitalDeficit_iI_pp0p0_c20260331_zgILkmuj4fi1" title="Working capital deficit"&gt;899,267&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#x2019;s officers and directors may, but is not obligated to, loan the Company funds as may be required (the &#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, the Company would repay such loaned amounts at that time. Up to $&lt;span id="xdx_905_eus-gaap--DebtConversionOriginalDebtAmount1_c20251001__20260331_z4du6WD6keXk" title="Conversion of debt"&gt;1,500,000&lt;/span&gt; of such Working Capital Loans may be converted into units upon consummation of the Business Combination at a price of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20260331_zha49kB2Q2Gc" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit. The units would be identical to the Private Placement Units. As of March&#160;31, 2026, the Company had no borrowings under the Working Capital Loans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In connection with the Company&#x2019;s assessment of going concern considerations in accordance with FASB ASC Topic 205-40, &#x201c;Presentation of Financial Statements &#x2014; Going Concern,&#x201d; the Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating its business. However, if the estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial Business Combination. The Company has the Combination Period to complete the initial Business Combination. Management has determined that the Company has sufficient funds to finance the working capital needs of the Company within one year from the date of issuance of the financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</rfa:LiquidityAndCapitalResourcesPolicyTextBlock>
    <us-gaap:UnsecuredDebt
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000409"
      unitRef="USD">150000</us-gaap:UnsecuredDebt>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000410"
      unitRef="USD">933390</us-gaap:Cash>
    <rfa:WorkingCapitalDeficit
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000412"
      unitRef="USD">899267</rfa:WorkingCapitalDeficit>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000414"
      unitRef="USD">1500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000416"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <rfa:EmergingGrowthCompanyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000418">&lt;p id="xdx_843_ecustom--EmergingGrowthCompanyPolicyTextBlock_zWS7LMpyEH66" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z3sCjMk6awYd"&gt;Emerging Growth Company&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act of 1933, as amended (the &#x201c;Securities
Act&#x201d;), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), and it may take
advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging
growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation
requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and
shareholder approval of any golden parachute payments not previously approved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</rfa:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-10-01to2026-03-31" id="Fact000425">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zgILAhw555Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_z76cHeNcThz5"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of this unaudited condensed financial statement in conformity with US GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000427">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zkCDlZM9kdaj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zikynz4Ls5ec"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $&lt;span id="xdx_90C_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_c20260331_zKFqbklCrEYe" title="Cash"&gt;933,390&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0d_c20250930_zfYK1oOz1TIh" title="Cash"&gt;0&lt;/span&gt; in cash and &lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20260331_zecewXHUV8Nj" title="Cash equivalents"&gt;&lt;span id="xdx_90B_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0d_do_c20250930_zyO1eThGUYIk" title="Cash equivalents"&gt;no&lt;/span&gt;&lt;/span&gt; cash equivalents as of March 31, 2026 and September 30, 2025, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000429"
      unitRef="USD">933390</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000431"
      unitRef="USD">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000433"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000435"
      unitRef="USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <rfa:CashHeldinTrustAccountPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000437">&lt;p id="xdx_849_ecustom--CashHeldinTrustAccountPolicyTextBlock_zTFppfFETPT5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zc5hvS4oL489"&gt;Cash Held in Trust Account&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;As of March 31, 2026, the
assets held in the Trust Account, amounting to $&lt;span id="xdx_908_eus-gaap--AssetsHeldInTrust_c20260331_pp0p" title="Cash held in Trust Account"&gt;100,403,232&lt;/span&gt;, were held in cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</rfa:CashHeldinTrustAccountPolicyTextBlock>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000439"
      unitRef="USD">100403232</us-gaap:AssetsHeldInTrust>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-10-01to2026-03-31" id="Fact000441">&lt;p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zdlgpl3dm5o2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zZSbCs5fq5Ei"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $&lt;span id="xdx_907_eus-gaap--CashFDICInsuredAmount_iI_c20260331_zGzLNcMYvQa2" title="Federal deposit insurance corporation coverage limit"&gt;250,000&lt;/span&gt;. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <rfa:DeferredOfferingCostsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000449">&lt;p id="xdx_847_ecustom--DeferredOfferingCostsPolicyTextBlock_zLvheVFDStAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zgmVZZshnAvb"&gt;Offering Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company complies with the requirements of
the FASB ASC 340-10-S99 and SEC Staff Accounting Bulletin Topic 5A, &#x201c;Expenses of Offering&#x201d;. Offering costs consist
principally of professional and registration fees that are related to the Initial Public Offering. Offering costs allocated to the
Public Shares were charged to temporary equity, and offering costs allocated to Public Rights and Private Placement Units were
charged to shareholders&#x2019; equity, as both the Public Rights and Private Placement Rights, after management&#x2019;s evaluation,
were accounted for under equity treatment. Accordingly, $&lt;span id="xdx_90E_ecustom--OfferingCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicSharesMember_zFlu1ZnGHrT1" title="Offering costs"&gt;2,873,644&lt;/span&gt;
was allocated to Public Shares and charged to temporary equity, and $&lt;span id="xdx_900_ecustom--OfferingCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicRightsMember_zlfpAKTETN78" title="Offering costs"&gt;1,834,742&lt;/span&gt;
was allocated to Public Rights and Private Placement Units and charged to shareholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





</rfa:DeferredOfferingCostsPolicyTextBlock>
    <rfa:OfferingCosts
      contextRef="From2025-10-012026-03-31_custom_PublicSharesMember"
      decimals="0"
      id="Fact000451"
      unitRef="USD">2873644</rfa:OfferingCosts>
    <rfa:OfferingCosts
      contextRef="From2025-10-012026-03-31_custom_PublicRightsMember"
      decimals="0"
      id="Fact000453"
      unitRef="USD">1834742</rfa:OfferingCosts>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000455">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zBymHXdpfR39" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_ze1We6AdDgBe"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, &#x201c;&lt;i&gt;Income Taxes&lt;/i&gt;.&#x201d; Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March 31, 2026 and September 30, 2025. The Company is currently not aware of any issues under review that could result in significant payments, accruals, or material deviation from its position. The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company&#x2019;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. In accordance with Cayman income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company&#x2019;s financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2025-10-01to2026-03-31" id="Fact000457">&lt;p id="xdx_845_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zdQ4dtp16ly" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_zHq546xGKkHc"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under FASB ASC 820, &#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt;,&#x201d; approximates the carrying amounts represented in the unaudited condensed balance sheet, primarily due to their short-term nature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share Rights&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounted for the Public Rights and Private Placement Rights issued in connection with the Initial Public Offering and the private placement in accordance with the guidance contained in FASB ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d;. Accordingly, the Company evaluated and classified the Share Rights under equity treatment at their assigned values.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000464">&lt;p id="xdx_843_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zIKQ5PfoF7i9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zP1o6qsxnDAj"&gt;Share-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for share awards in accordance with FASB ASC Topic 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (e.g., the occurrence of Initial Public Offering). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2025-10-01to2026-03-31" id="Fact000466">&lt;p id="xdx_849_eus-gaap--DerivativesReportingOfDerivativeActivity_zljIzyAqNQng" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z0DE5W4ZjSv7"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, &#x201c;Derivatives and Hedging&#x201d;. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the unaudited condensed balance sheet as current or non-current based on whether or not net cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The underwriters&#x2019; over-allotment option is deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and was accounted for as a liability pursuant to ASC 480 since the underwriters did not exercise their overallotment option at the closing of the Initial Public Offering. On February 19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20260201__20260219_z5fvzyoJc9Mi" title="Option forfeit"&gt;1,500,000&lt;/span&gt; Units, and the Company derecognized the over-allotment liability accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2026-02-012026-02-19"
      decimals="INF"
      id="Fact000468"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000470">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zYotJdcp1wzf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_z9uodEC9C0tj"&gt;Net Income per Ordinary Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The Company complies with accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. The condensed statements of operations include a presentation of income per redeemable share and income per non-redeemable share following the two-class method of income per share. In order to determine the net income attributable to both the redeemable shares and non-redeemable shares, the Company first considered the undistributed income allocable to both the redeemable shares and non-redeemable shares and the undistributed income is calculated using the total net income less any dividends paid. The Company then allocated the undistributed income ratably based on the weighted average number of shares outstanding between the redeemable and non-redeemable shares. Any remeasurement of the accretion to redemption value of the common shares subject to possible redemption was considered to be dividends paid to the public shareholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;The calculation of diluted income per ordinary share does not consider the effect of the rights issued in connection with the Initial Public Offering and the Private Placement Units since the exercise of the units is contingent upon the occurrence of future events. The rights are exercisable to purchase &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260331_ztF2Gpyl8EWi" title="Shares exercisable"&gt;1,000,000&lt;/span&gt; Ordinary Shares in the aggregate. The &lt;span id="xdx_905_ecustom--OrdinarySharesSubjectToForfeiture_iI_c20260331_zz4M5Jy7brYb" title="Ordinary shares subject to forfeiture"&gt;500,000&lt;/span&gt; ordinary shares that were subject to forfeiture if the over-allotment option was not exercised by the underwriters were not included in the calculation of weighted average shares outstanding. As of March&#160;31, 2026 and September 30, 2025, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares that then share in the earnings of the Company. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Net income per share, basic and diluted, for non-redeemable ordinary shares is calculated by dividing the net loss, adjusted for income attributable to redeemable ordinary shares, by the weighted average number of non-redeemable ordinary shares outstanding for the period. Non-redeemable ordinary shares include the Founder Shares and the Private Shares as these shares do not have any redemption features and do not participate in the income earned on the Trust Account.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts):&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOtTy0GAQmj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B9_z7rBXlhv8M1e" style="display: none"&gt;Basic and diluted net income per ordinary share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260101__20260331_zaoIslaymaof" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20251001__20260331_zp7YkB3eKHJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended &lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;
Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0d_zBehFIO6gTs9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;725,986&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;673,033&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_pp0d_zr9qZUUBOkch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue_pp0d_z6xq6rSiGWlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Net Income including accretion of ordinary shares to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,754&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;269,801&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zihxbn7Z2ET1" title="Net Income"&gt;179,024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zKIgWR5E8hp1" title="Net Income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zruhXWp6Yz2g" title="Net Income"&gt;104,476&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zcr4YQCVWxbd" title="Net Income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zNxLLXI6ish8" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zp7ghk8Yruug" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0502"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_znqDtO0Gv2J9" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zULx6jCSQ6b7" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Allocation of net income&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zTp8r1zueqvg" title="Allocation of net income"&gt;582,256&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zUiLzOHIDxt7" title="Allocation of net income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zLJ7NVAN6Xv2" title="Allocation of net income"&gt;507,708&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zxntwKURzTFf" title="Allocation of net income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zULNoydRXX5" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjJVdeSMPg81" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;4,666,667&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zluo3enOxahd" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zH4MpOBz1KT2" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,746,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zoWPSnJnwshj" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_z0ib8qaoy6Zc" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;2,307,692&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zsXc5y4uESGk" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zmfFwOYx3p8h" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,651,740&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zhyWwQHVrf5j" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zzh4sn32iSue" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjZBfZERHHHa" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_z9trRFdd8iZ7" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A1_zpMNgHheVSpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

















</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000472"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <rfa:OrdinarySharesSubjectToForfeiture
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000474"
      unitRef="Shares">500000</rfa:OrdinarySharesSubjectToForfeiture>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000481">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zOtTy0GAQmj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B9_z7rBXlhv8M1e" style="display: none"&gt;Basic and diluted net income per ordinary share&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20260101__20260331_zaoIslaymaof" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_491_20251001__20260331_zp7YkB3eKHJg" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended &lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt;
Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pp0d_zBehFIO6gTs9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;725,986&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;673,033&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_pp0d_zr9qZUUBOkch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue_pp0d_z6xq6rSiGWlj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Net Income including accretion of ordinary shares to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;322,754&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;269,801&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Three Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; Six Months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Redeemable&lt;br/&gt; ordinary shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Non-redeemable&lt;br/&gt; Ordinary Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Numerator&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left"&gt;Net Income&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zihxbn7Z2ET1" title="Net Income"&gt;179,024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zKIgWR5E8hp1" title="Net Income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zruhXWp6Yz2g" title="Net Income"&gt;104,476&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--NetIncomeLossAttributableToParentDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zcr4YQCVWxbd" title="Net Income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Remeasurement for ordinary shares subject to redemption&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zNxLLXI6ish8" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zp7ghk8Yruug" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0502"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_znqDtO0Gv2J9" title="Remeasurement for ordinary shares subject to redemption"&gt;403,232&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--RemeasurementForOrdinarySharesSubjectToRedemption_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zULx6jCSQ6b7" title="Remeasurement for ordinary shares subject to redemption"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0506"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"&gt;Allocation of net income&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_900_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zTp8r1zueqvg" title="Allocation of net income"&gt;582,256&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--AllocationOfNetIncome_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zUiLzOHIDxt7" title="Allocation of net income"&gt;143,730&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zLJ7NVAN6Xv2" title="Allocation of net income"&gt;507,708&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_ecustom--AllocationOfNetIncome_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zxntwKURzTFf" title="Allocation of net income"&gt;165,325&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted weighted average shares outstanding&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zULNoydRXX5" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjJVdeSMPg81" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;4,666,667&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zluo3enOxahd" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zH4MpOBz1KT2" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,746,666&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zoWPSnJnwshj" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_z0ib8qaoy6Zc" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;2,307,692&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zsXc5y4uESGk" title="Weighted average shares outstanding of redeemable ordinary shares, Basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zmfFwOYx3p8h" title="Weighted average shares outstanding of redeemable ordinary shares, Diluted"&gt;3,651,740&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Basic and diluted net income per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zhyWwQHVrf5j" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareBasic_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_zzh4sn32iSue" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_901_eus-gaap--EarningsPerShareDiluted_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_zjZBfZERHHHa" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--RedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--EarningsPerShareBasic_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_z9trRFdd8iZ7" title="Basic net income per redeemable ordinary share"&gt;&lt;span id="xdx_900_eus-gaap--EarningsPerShareDiluted_c20251001__20260331__us-gaap--StatementEquityComponentsAxis__custom--NonRedeemableOrdinarySharesMember_pd" title="Diluted net income per redeemable ordinary share"&gt;0.05&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">725986</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000484"
      unitRef="USD">673033</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">-403232</rfa:RemeasurementForOrdinarySharesSubjectToRedemption>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000487"
      unitRef="USD">-403232</rfa:RemeasurementForOrdinarySharesSubjectToRedemption>
    <rfa:NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">322754</rfa:NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue>
    <rfa:NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000490"
      unitRef="USD">269801</rfa:NetIncomeIncludingAccretionOfOrdinarySharesToRedemptionValue>
    <us-gaap:NetIncomeLossAttributableToParentDiluted
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000492"
      unitRef="USD">179024</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000494"
      unitRef="USD">143730</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000496"
      unitRef="USD">104476</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <us-gaap:NetIncomeLossAttributableToParentDiluted
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000498"
      unitRef="USD">165325</us-gaap:NetIncomeLossAttributableToParentDiluted>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000500"
      unitRef="USD">403232</rfa:RemeasurementForOrdinarySharesSubjectToRedemption>
    <rfa:RemeasurementForOrdinarySharesSubjectToRedemption
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000504"
      unitRef="USD">403232</rfa:RemeasurementForOrdinarySharesSubjectToRedemption>
    <rfa:AllocationOfNetIncome
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000508"
      unitRef="USD">582256</rfa:AllocationOfNetIncome>
    <rfa:AllocationOfNetIncome
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000510"
      unitRef="USD">143730</rfa:AllocationOfNetIncome>
    <rfa:AllocationOfNetIncome
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000512"
      unitRef="USD">507708</rfa:AllocationOfNetIncome>
    <rfa:AllocationOfNetIncome
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="0"
      id="Fact000514"
      unitRef="USD">165325</rfa:AllocationOfNetIncome>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000516"
      unitRef="Shares">4666667</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000518"
      unitRef="Shares">4666667</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000520"
      unitRef="Shares">3746666</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">3746666</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000524"
      unitRef="Shares">2307692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000526"
      unitRef="Shares">2307692</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000528"
      unitRef="Shares">3651740</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000530"
      unitRef="Shares">3651740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000532"
      unitRef="USDPShares">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000534"
      unitRef="USDPShares">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000536"
      unitRef="USDPShares">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000538"
      unitRef="USDPShares">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000540"
      unitRef="USDPShares">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-10-012026-03-31_custom_RedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000542"
      unitRef="USDPShares">0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000544"
      unitRef="USDPShares">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-10-012026-03-31_custom_NonRedeemableOrdinarySharesMember"
      decimals="INF"
      id="Fact000546"
      unitRef="USDPShares">0.05</us-gaap:EarningsPerShareDiluted>
    <rfa:OrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000553">&lt;p id="xdx_84A_ecustom--OrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock_z5vQwPQ72Rn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zVsNsNlOks2b"&gt;Ordinary Shares Subject to Possible Redemption&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company&#x2019;s liquidation, if there is a shareholder vote (A) to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the Public Shares if the Company does not complete an initial Business Combination within the completion window or (B) with respect to any other material provisions relating to shareholders&#x2019; rights or pre-initial Business Combination activity, or if there is a shareholder vote or tender offer in connection with the Company&#x2019;s initial Business Combination. In accordance with ASC 480-10-S99, the Company classifies Public Shares subject to redemption outside of permanent equity as the redemption provisions are not solely within the control of the Company. The Company recognizes changes in redemption value immediately as they occur and will adjust the carrying value of redeemable shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption value. The change in the carrying value of redeemable shares will result in charges against additional paid-in capital (to the extent available) and accumulated deficit. Accordingly, as of March&#160;31, 2026, the ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the shareholders&#x2019; equity section of the Company&#x2019;s unaudited condensed balance sheet. As of March&#160;31, 2026, the ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--TemporaryEquityTableTextBlock_zkusVmplSvr8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span id="xdx_8BD_z0KWW4Wlvbii"&gt;&lt;span id="xdx_8B9_zu2jEARQ72Tf" style="display: none"&gt;Schedule of ordinary shares subject to possible redemption&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Gross proceeds&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iS_c20251001__20260331_zx4Yllrgu96k" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OrdinarySharesSubjectToPossibleRedemption_iS_c20251001__20260331_zCP5CPbl6YUa" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to Public Rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ProceedsAllocatedToPublicRights_c20251001__20260331_zXmKL6tlmVL6" style="text-align: right" title="Proceeds allocated to Public Rights"&gt;(2,003,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ProceedsAllocatedToOverallotmentOption_c20251001__20260331_zdMhSa7GLw4h" style="text-align: right" title="Proceeds allocated to over-allotment option"&gt;(422,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary shares issuance cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--PublicSharesIssuanceCosts_c20251001__20260331_zOLe07NOmEj4" style="text-align: right" title="Public Shares issuance costs"&gt;(2,873,644&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20251001__20260331_zqHQeuMRMGJh" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of carrying value to redemption value"&gt;5,701,876&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary Shares subject to possible redemption, March&#160;31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iE_c20251001__20260331_zsmJ2GjBt6ka" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OrdinarySharesSubjectToPossibleRedemption_iE_c20251001__20260331_zqrouuBcG2R5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zIleuDzohXWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</rfa:OrdinarySharesSubjectToPossibleRedemptionPolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000555">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--TemporaryEquityTableTextBlock_zkusVmplSvr8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;&lt;span id="xdx_8BD_z0KWW4Wlvbii"&gt;&lt;span id="xdx_8B9_zu2jEARQ72Tf" style="display: none"&gt;Schedule of ordinary shares subject to possible redemption&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Gross proceeds&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iS_c20251001__20260331_zx4Yllrgu96k" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--OrdinarySharesSubjectToPossibleRedemption_iS_c20251001__20260331_zCP5CPbl6YUa" style="width: 9%; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,000,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Less:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to Public Rights&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ProceedsAllocatedToPublicRights_c20251001__20260331_zXmKL6tlmVL6" style="text-align: right" title="Proceeds allocated to Public Rights"&gt;(2,003,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Proceeds allocated to over-allotment option&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--ProceedsAllocatedToOverallotmentOption_c20251001__20260331_zdMhSa7GLw4h" style="text-align: right" title="Proceeds allocated to over-allotment option"&gt;(422,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary shares issuance cost&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--PublicSharesIssuanceCosts_c20251001__20260331_zOLe07NOmEj4" style="text-align: right" title="Public Shares issuance costs"&gt;(2,873,644&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -0.125in; padding-left: 0.125in"&gt;Plus:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Accretion of carrying value to redemption value&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20251001__20260331_zqHQeuMRMGJh" style="border-bottom: Black 1pt solid; text-align: right" title="Accretion of carrying value to redemption value"&gt;5,701,876&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"&gt;Ordinary Shares subject to possible redemption, March&#160;31, 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98A_ecustom--OrdinarySharesSubjectToPossibleRedemptionShares_iE_c20251001__20260331_zsmJ2GjBt6ka" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption, shares"&gt;10,000,000&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td id="xdx_981_ecustom--OrdinarySharesSubjectToPossibleRedemption_iE_c20251001__20260331_zqrouuBcG2R5" style="border-bottom: Black 2.5pt double; text-align: right" title="Ordinary Shares subject to possible redemption"&gt;100,403,232&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:TemporaryEquityTableTextBlock>
    <rfa:OrdinarySharesSubjectToPossibleRedemptionShares
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000557"
      unitRef="Shares">10000000</rfa:OrdinarySharesSubjectToPossibleRedemptionShares>
    <rfa:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2025-09-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">100000000</rfa:OrdinarySharesSubjectToPossibleRedemption>
    <rfa:ProceedsAllocatedToPublicRights
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">-2003000</rfa:ProceedsAllocatedToPublicRights>
    <rfa:ProceedsAllocatedToOverallotmentOption
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">-422000</rfa:ProceedsAllocatedToOverallotmentOption>
    <rfa:PublicSharesIssuanceCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000565"
      unitRef="USD">-2873644</rfa:PublicSharesIssuanceCosts>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000567"
      unitRef="USD">5701876</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <rfa:OrdinarySharesSubjectToPossibleRedemptionShares
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000569"
      unitRef="Shares">10000000</rfa:OrdinarySharesSubjectToPossibleRedemptionShares>
    <rfa:OrdinarySharesSubjectToPossibleRedemption
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000571"
      unitRef="USD">100403232</rfa:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000573">&lt;p id="xdx_841_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z5HNLxjIxg1e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1H0wFJvopSi"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In November 2023, the FASB issued ASU 2023-07,
&#x201c;Segment reporting (Topic 280): Improvements to Reportable Segment Disclosures&#x201d; (&#x201c;ASU 2023-07&#x201d;). The amendments
in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief
operating decision maker (&#x201c;CODM&#x201d;), as well as the aggregate amount of other segment items included in the reported measure
of segment profit or loss. The ASU requires that a public entity disclose the title and position of the CODM and an explanation of how
the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources.
Public entities will be required to provide all annual disclosures currently required by Topic 280 in interim periods, and entities with
a single reportable segment are required to provide all the disclosures required by the amendments in this ASU and existing segment disclosures
in Topic 280. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning
after December&#160;15, 2024, with early adoption permitted. The Company adopted ASU 2023-07 on September 15, 2025, the date of its incorporation.
Please refer to Note 9&#x2014; SEGMENT INFORMATION.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000575">&lt;p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zNmoLbdmF7ka" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zrCpBYuN3OU1"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;In December 2025, the
FASB issued ASU 2025-11 &#x201c;Interim Reporting (Topic 270): Narrow Scope Improvements (&#x201c;ASU 2025-11&#x201d;), to improve the
guidance for interim reporting and clarify when that guidance is applicable. The ASU 2025-11 provides a comprehensive list of
required disclosures and also requires entities to disclose events since the last annual reporting period that have a material
impact on the entity. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after
December 15, 2027, for public business entities and for interim reporting periods within annual reporting periods beginning after December 15, 2028, for
entities other than public business entities. Early adoption is permitted. Management is currently evaluating ASU 2025-11 to determine
its impact on the Company&#x2019;s disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statement.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;














&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rfa:InitialPublicOfferingTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000581">&lt;p id="xdx_800_ecustom--InitialPublicOfferingTextBlock_zqrBiH6OKps6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 3 &#x2014; &lt;span id="xdx_829_zS7bOKXIt795"&gt;INITIAL PUBLIC OFFERING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In the Initial Public Offering on February&#160;17, 2026, the Company sold &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zqzd7rQaalYf" title="Sale of units in initial public offering"&gt;10,000,000&lt;/span&gt; Units at a price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z2JEhY3JyOTb" title="Sale of shares, price per share"&gt;10.00&lt;/span&gt; per Unit. Each Unit consists of one Public Share and one Public Right, with each Public Right entitling the holder to receive one-tenth (1/10) of one ordinary share upon the consummation of an initial Business Combination. Total offering costs allocated to the Initial Public Offering that were charged to additional paid-in capital amounted to $&lt;span id="xdx_909_ecustom--OfferingCosts_c20251001__20260331_z28z7gY0mPIf" title="Offering costs"&gt;58,990&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</rfa:InitialPublicOfferingTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000583"
      unitRef="Shares">10000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-17_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000585"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <rfa:OfferingCosts
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000587"
      unitRef="USD">58990</rfa:OfferingCosts>
    <rfa:PrivatePlacementTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000589">&lt;p id="xdx_806_ecustom--PrivatePlacementTextBlock_zAgO6DpZrmd7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 4 &#x2014; &lt;span id="xdx_823_zBKmls2JNti2"&gt;PRIVATE PLACEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Simultaneously
with the closing of the Initial Public Offering, the Sponsor and its designees and EBC, purchased an aggregate of &lt;span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z9IRR4jPYhU8"&gt;350,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
Placement Units, at a price of $&lt;span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zLjb4e2lY9E5"&gt;10.00 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
Private Placement Unit, or $&lt;span id="xdx_906_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pp0p0_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zq90qDnEgrwd"&gt;3,500,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in
the aggregate, in a private placement, of which &lt;span id="xdx_90A_ecustom--PurchaseOfShares_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zkjh79tuTMtf"&gt;250,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
Placement Units were purchased by the Sponsor and its designees, and &lt;span id="xdx_907_ecustom--PurchaseOfShares_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--EarlyBirdCapitalIncMember_zQajAd30vNF4" title="Purchase of shares"&gt;100,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Private
Placement Units were purchased by EBC. Each Unit consists of one Private Share and one Private Placement Right, with each
Private Placement Right entitling the holder to receive one-tenth of one ordinary share. A portion of the proceeds from the sale of
the Private Placement Units were added to the net proceeds from the Initial Public Offering held in the Trust Account. If the
Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement
Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable
law). The Private Placement Units and underlying securities will not be transferable, assignable, or salable until the completion of
a Business Combination, subject to certain exceptions. Total offering costs allocated to the Private Placement Units that were
charged to additional paid-in capital amounted to $&lt;span id="xdx_902_ecustom--OfferingCosts_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_znOz0A951hr5" title="Offering costs"&gt;1,763,325&lt;/span&gt;,
which includes the impact of the fair value of Founder Shares transferred to third-party designees of $&lt;span id="xdx_90C_ecustom--FounderSharesTransfered_iI_c20260331_zbCWFNFsv2S" title="Founder shares transfered"&gt;1,747,800&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;



</rfa:PrivatePlacementTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000590"
      unitRef="Shares">350000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000591"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">3500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <rfa:PurchaseOfShares
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">250000</rfa:PurchaseOfShares>
    <rfa:PurchaseOfShares
      contextRef="From2026-02-012026-02-17_us-gaap_PrivatePlacementMember_custom_EarlyBirdCapitalIncMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Shares">100000</rfa:PurchaseOfShares>
    <rfa:OfferingCosts
      contextRef="From2025-10-012026-03-31_us-gaap_PrivatePlacementMember"
      decimals="0"
      id="Fact000597"
      unitRef="USD">1763325</rfa:OfferingCosts>
    <rfa:FounderSharesTransfered
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000599"
      unitRef="USD">1747800</rfa:FounderSharesTransfered>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000601">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zfroBwLTcEoh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 5 &#x2014; &lt;span id="xdx_826_zpLGAKB70lI8"&gt;RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Founder Shares&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September&#160;30, 2025, the Sponsor received &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250901__20250930__us-gaap--RelatedPartyTransactionAxis__custom--FounderMember_zZmFGlLaeQmd" title="Aggregate value of shares, shares"&gt;3,833,333&lt;/span&gt; of the Company&#x2019;s ordinary shares (&#x201c;Founder Shares&#x201d;) in exchange for $&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20250901__20250930__us-gaap--RelatedPartyTransactionAxis__custom--FounderMember_z8m7jQC7I1Ik" title="Aggregate value of shares"&gt;25,000&lt;/span&gt; paid to cover certain offering costs by the Company. Up to &lt;span id="xdx_907_ecustom--SharesSubjectToForfeiture_c20250901__20250930__us-gaap--RelatedPartyTransactionAxis__custom--FounderMember_zQJ3CHF12Ypk" title="Shares subject to forfeiture"&gt;500,000&lt;/span&gt; of such Founder Shares are subject to forfeiture to the extent that the underwriters&#x2019; over-allotment is not exercised in full. On February&#160;19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional &lt;span id="xdx_904_eus-gaap--SharesIssued_iI_c20260219_zF0xkMPqz7Cl" title="Shares issued"&gt;1,500,000&lt;/span&gt; Units, resulting in the subsequent forfeiture of the &lt;span id="xdx_908_ecustom--SharesSubjectToForfeiture_c20260201__20260219_zhRlIsKJPDs8" title="Shares subject to forfeiture"&gt;500,000&lt;/span&gt; Founder Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) six months after the completion of the initial Business Combination and (B) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar transaction after the initial Business Combination that results in all public shareholders having the right to exchange their ordinary shares for cash, securities or other property.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October&#160;9, 2025, the Company issued to EBC &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20251009_zEgxFo2FhdJi" title="Shares issued"&gt;250,000&lt;/span&gt; Ordinary Shares for a total consideration of $&lt;span id="xdx_90A_ecustom--BusinessCombinationConsiderationTransferred_c20251001__20251009_zVpv2aw0q6i7" title="Total consideration"&gt;1,630&lt;/span&gt; or approximately $0.007 per share (the &#x201c;EBC founder shares&#x201d;). The issuance of EBC founder shares is in the scope of FASB ASC 718. Under FASB ASC 718, share-based compensation associated with equity classified awards is measured at fair value upon the assignment date. Further, the issuance of the EBC founder shares should be accounted for as an offering cost in accordance with SAB Topic 5A, Expenses of Offering, since the EBC founder shares are deemed to be underwriters&#x2019; compensation by FINRA pursuant to Rule&#160;5110 of the FINRA Manual. The Company estimated the fair value in excess of costs of the &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_c20251009_z6i7794wP9y" title="Shares issued"&gt;250,000&lt;/span&gt; EBC founder shares to be $&lt;span id="xdx_90E_ecustom--FairValueOfFounderShares_c20251001__20251009_zfwtTB0W5lLf" title="Fair value of founder shares"&gt;501,500&lt;/span&gt; or $2.006 per share based on the third-party valuation obtained by the Company. Accordingly, $&lt;span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20251009_zjB1zJ9IkMF" title="Deferred offering costs"&gt;501,500&lt;/span&gt; has been recorded as a deferred offering costs on October&#160;9, 2025, with a corresponding increase in additional paid-in capital. The Company established the initial fair value for the EBC founder shares on October&#160;9, 2025, the date of the issuance, using PWERM model, and classified as Level 3 at the measurement date due to the use of unobservable inputs including the probability of a Business Combination, the probability of the initial public offering, and other risk factors. The primary assumptions used in the valuation of EBC founder shares were (i) share price of $&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_c20251009_z7xKGQ7LxkQf" title="Share price"&gt;9.769&lt;/span&gt; (ii) restricted term of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20251001__20251009_zVIFMHn9wapl" title="Restricted term"&gt;2.75&lt;/span&gt; years (iii) risk-free rate of &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20251001__20251009_zOSgTrd2ob7b" title="Risk-free rate"&gt;3.59&lt;/span&gt;% (iv) volatility of &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20251001__20251009_zxTw85Qn7Vg9" title="Volatility"&gt;8.3&lt;/span&gt;% (v) likelihood of initial Business Combination of &lt;span id="xdx_905_ecustom--InitialBusinessCombinationPercentage_iI_dp_c20251009_zjyflworn9P2" title="Initial business combination, percentage"&gt;23.6&lt;/span&gt;% and (vi) implied discount for lack of marketability of &lt;span id="xdx_908_eus-gaap--ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_dp_c20251001__20251009_zNFdkKMxJC34" title="Implied discount"&gt;3.2&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 17, 2026, the Sponsor transferred &lt;span id="xdx_90B_ecustom--FounderShares_iI_c20260217_zVQo2QnAPddd" title="Founder shares"&gt;900,000&lt;/span&gt; Founder Shares to the third-party designees of the Sponsor for their participation in the private placement of the Company. The Founder Shares transferred was placed into an escrow account maintained by Continental Stock Transfer &amp;amp; Trust Company acting as escrow agent and will not be transferred, assigned, sold or released from escrow until six months after the consummation of the Business Combination, or earlier, if, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their shares for cash, securities or other property. The transfer of the Founder Shares to the third-party designees is in the scope of SEC&#x2019;s Staff Accounting Bulletin (&#x201c;SAB&#x201d;) Topic 5A, Expenses of Offering, which indicates that &#x201c;Specific incremental costs directly attributable to a proposed or actual offering of securities may properly be deferred and charged against the gross proceeds of the offering&#x201d;. The total fair value of the &lt;span id="xdx_90B_ecustom--FounderShares_iI_c20260217_zpkQnqoPugZ3" title="Founder shares"&gt;900,000&lt;/span&gt; Founder Shares on February 17, 2026 was $1,747,800 or $1.942 per share. The Company established the initial fair value of the Founder Shares on February 17, 2026, using Probability-Weighted Expected Return Method (&#x201c;PWERM&#x201d;) model, and classified as Level 3 at the measurement date due to the use of unobservable inputs including the probability of a Business Combination, the probability of the initial public offering, and other risk factors. The primary assumptions used in the valuation of Founder Shares were (i) share price of $&lt;span id="xdx_902_eus-gaap--SharePrice_iI_c20260217_zgBfC1MgM2Yb" title="Share price"&gt;9.7997&lt;/span&gt; (ii) restricted term of &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260217_zPTtI39VX6O2" title="Restricted term"&gt;2.25&lt;/span&gt; years (iii) risk-free rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260201__20260217_zkhU1eWjkB19" title="Risk-free rate"&gt;3.44&lt;/span&gt;% (iv) volatility of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260201__20260217_z0WdUmXqP9Rf" title="Volatility"&gt;8.8&lt;/span&gt;% (v) likelihood of initial Business Combination of &lt;span id="xdx_908_ecustom--InitialBusinessCombinationPercentage_iI_dp_c20260217_z5QCikCHUJb8" title="Initial business combination, percentage"&gt;20.4&lt;/span&gt;% and (vi) implied discount for lack of marketability of &lt;span id="xdx_903_eus-gaap--ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_dp_c20260201__20260217_zCF7AS03iP4j" title="Implied discount"&gt;3.0&lt;/span&gt;%. The fair value of Founder Shares transferred to third-party designees of $1,747,800 was recorded as offering costs and was allocated solely to the Private Placement Units that was charged to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Promissory Note &#x2014; Related Party&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September&#160;30, 2025, the Sponsor has agreed to loan the Company an aggregate of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20250930__us-gaap--LongtermDebtTypeAxis__custom--PromissoryNoteRelatedPartyMember_z5j2J1yMTOij"&gt;150,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;to be used for a portion of the expenses of the Initial Public Offering. The loans are non-interest bearing, unsecured and due at the closing of the Initial Public Offering. On February&#160;25, 2026, the Company repaid the total outstanding balance of the promissory note amounting to $&lt;span id="xdx_900_ecustom--PromissoryNoteRelatedParty_iI_c20260225_zgUAVDe1wNkk" title="Promissory note related party"&gt;150,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and the note is terminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Due to Sponsor&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2026, the balance of $&lt;span id="xdx_902_ecustom--UnpaidAdministrativeServiceFee_c20260101__20260331_zSvX6oRVLiY4" title="Unpaid administrative service fee"&gt;16,071&lt;/span&gt; due to Sponsor represents the unpaid administrative service fee as described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Administration Fee&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company entered into an agreement with the Sponsor commencing on February&#160;12, 2026 through the earlier of the Company&#x2019;s consummation of initial Business Combination and its liquidation, to pay an aggregate of $&lt;span id="xdx_906_ecustom--OfficeSpace_c20251001__20260331_zRVib5OLdKbk" title="Office space"&gt;10,000&lt;/span&gt; per month for office space, utilities, and secretarial and administrative support services. For the three and six month ended March 31, 2026, $&lt;span id="xdx_906_eus-gaap--AdministrativeFeesExpense_c20251001__20260331_zxuQQBLouLf3" title="Administration fee"&gt;16,071&lt;/span&gt; amounts were incurred under this agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Related Party Loans&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsor or an affiliate of the Sponsor or certain of our officers and directors may, but are not obligated to, loan the Company funds as may be required on a non-interest basis. If we complete an initial Business Combination, the Company would repay such loaned amounts. In the event that the initial Business Combination does not close, the Company may use amounts held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used for such repayment. Up to $&lt;span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_c20251001__20260331_zHt956Rb91S2" title="Conversion of debt"&gt;1,500,000&lt;/span&gt; of such loans may be convertible into units of the post Business Combination entity at a price of $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20260331_z1YUcO7hLnif" title="Sale of units per share"&gt;10.00&lt;/span&gt; per unit at the option of the lender. Such units would be identical to the Private Placement Units. Except as set forth above, the terms of such loans, if any, have not been determined and no written agreements exist with respect to such loans. As of March&#160;31, 2026, no such Working Capital Loans were outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
















</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-09-012025-09-30_custom_FounderMember"
      decimals="INF"
      id="Fact000603"
      unitRef="Shares">3833333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-09-012025-09-30_custom_FounderMember"
      decimals="0"
      id="Fact000605"
      unitRef="USD">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rfa:SharesSubjectToForfeiture
      contextRef="From2025-09-012025-09-30_custom_FounderMember"
      decimals="INF"
      id="Fact000607"
      unitRef="Shares">500000</rfa:SharesSubjectToForfeiture>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-02-19"
      decimals="INF"
      id="Fact000609"
      unitRef="Shares">1500000</us-gaap:SharesIssued>
    <rfa:SharesSubjectToForfeiture
      contextRef="From2026-02-012026-02-19"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">500000</rfa:SharesSubjectToForfeiture>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-10-09"
      decimals="INF"
      id="Fact000613"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <rfa:BusinessCombinationConsiderationTransferred
      contextRef="From2025-10-012025-10-09"
      decimals="0"
      id="Fact000615"
      unitRef="USD">1630</rfa:BusinessCombinationConsiderationTransferred>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-10-09"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">250000</us-gaap:SharesIssued>
    <rfa:FairValueOfFounderShares
      contextRef="From2025-10-012025-10-09"
      decimals="0"
      id="Fact000619"
      unitRef="USD">501500</rfa:FairValueOfFounderShares>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2025-10-09"
      decimals="0"
      id="Fact000621"
      unitRef="USD">501500</us-gaap:DeferredOfferingCosts>
    <us-gaap:SharePrice
      contextRef="AsOf2025-10-09"
      decimals="INF"
      id="Fact000623"
      unitRef="USDPShares">9.769</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2025-10-012025-10-09" id="Fact000625">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2025-10-012025-10-09"
      decimals="INF"
      id="Fact000627"
      unitRef="Ratio">0.0359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2025-10-012025-10-09"
      decimals="INF"
      id="Fact000629"
      unitRef="Ratio">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <rfa:InitialBusinessCombinationPercentage
      contextRef="AsOf2025-10-09"
      decimals="INF"
      id="Fact000631"
      unitRef="Ratio">0.236</rfa:InitialBusinessCombinationPercentage>
    <us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate
      contextRef="From2025-10-012025-10-09"
      decimals="INF"
      id="Fact000633"
      unitRef="Ratio">0.032</us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate>
    <rfa:FounderShares
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact000640"
      unitRef="Shares">900000</rfa:FounderShares>
    <rfa:FounderShares
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact000642"
      unitRef="Shares">900000</rfa:FounderShares>
    <us-gaap:SharePrice
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact000644"
      unitRef="USDPShares">9.7997</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2026-02-012026-02-17" id="Fact000646">P2Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000648"
      unitRef="Ratio">0.0344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000650"
      unitRef="Ratio">0.088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <rfa:InitialBusinessCombinationPercentage
      contextRef="AsOf2026-02-17"
      decimals="INF"
      id="Fact000652"
      unitRef="Ratio">0.204</rfa:InitialBusinessCombinationPercentage>
    <us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000654"
      unitRef="Ratio">0.030</us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-09-30_custom_PromissoryNoteRelatedPartyMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <rfa:PromissoryNoteRelatedParty
      contextRef="AsOf2026-02-25"
      decimals="0"
      id="Fact000657"
      unitRef="USD">150000</rfa:PromissoryNoteRelatedParty>
    <rfa:UnpaidAdministrativeServiceFee
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000659"
      unitRef="USD">16071</rfa:UnpaidAdministrativeServiceFee>
    <rfa:OfficeSpace
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000661"
      unitRef="USD">10000</rfa:OfficeSpace>
    <us-gaap:AdministrativeFeesExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000663"
      unitRef="USD">16071</us-gaap:AdministrativeFeesExpense>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000665"
      unitRef="USD">1500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000667"
      unitRef="USDPShares">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000674">&lt;p id="xdx_805_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zAOiUcOiggZ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 6 &#x2014; &lt;span id="xdx_826_ze6oXV0Xlagl"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The United States and global markets are experiencing volatility and disruption following the geopolitical instability resulting from the ongoing Russia-Ukraine conflict and the Israel-Hamas conflict. In response to the ongoing Russia-Ukraine conflict, the North Atlantic Treaty Organization (&#x201c;NATO&#x201d;) deployed additional military forces to eastern Europe, and the United States, the United Kingdom, the European Union and other countries have announced various sanctions and restrictive actions against Russia, Belarus and related individuals and entities, including the removal of certain financial institutions from the Society for Worldwide Interbank Financial Telecommunication payment system. Certain countries, including the United States, have also provided and may continue to provide military aid or other assistance to Ukraine and to Israel, increasing geopolitical tensions among a number of nations. The invasion of Ukraine by Russia and the Israel-Hamas conflict and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and its neighboring states and other countries have created global security concerns that could have a lasting impact on regional and global economies. Although the length and impact of the ongoing conflicts are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions and increased cyberattacks against U.S. companies. Additionally, any resulting sanctions could adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July&#160;4, 2025, President Trump signed into law the One Big Beautiful Bill Act (&#x201c;OBBBA&#x201d;). FASB ASC 740, &#x201c;Income Taxes&#x201d;, requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. The Company is currently evaluating the impact of the new law. However, none of the tax provisions are expected to have a significant impact on the Company&#x2019;s financial statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any of the above mentioned factors, or any other negative impact on the global economy, capital markets or other geopolitical conditions resulting from the Russian invasion of Ukraine, the Israel-Hamas conflict and subsequent sanctions or related actions, could adversely affect the Company&#x2019;s search for an initial Business Combination and any target business with which the Company may ultimately consummate an initial Business Combination.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Registration Rights&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The holders of the Founder Shares, EBC founder shares, Private Placement Units and any units that may be issued upon conversion of working capital loans (and all underlying securities) are entitled to registration rights pursuant to a registration rights agreement signed on February&#160;12, 2026 requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule&#160;415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Underwriting Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20251001__20260331_zTjnET02lMol" title="Option granted"&gt;1,500,000&lt;/span&gt; additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On February&#160;19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional &lt;span id="xdx_909_eus-gaap--SharesIssued_iI_c20260219_zVQiNSUlTeDe" title="Shares issued"&gt;1,500,000&lt;/span&gt; Units, resulting in the subsequent forfeiture of the &lt;span id="xdx_904_ecustom--SharesSubjectToForfeiture_c20260201__20260219_zeHl8tEm0qx3" title="Shares subject to forfeiture"&gt;500,000&lt;/span&gt; Founder Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
underwriters were entitled to a cash underwriting discount of $0.20 per Unit, or $&lt;span id="xdx_90B_eus-gaap--ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_pp0p0_c20251001__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zSm6xEzJhkF2"&gt;2,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in the aggregate, which was paid upon the closing
of the Initial Public Offering.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;























&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Business Combination Marketing Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company engaged EBC as an advisor in connection with its Business Combination to assist in holding meetings with the Company stockholders to discuss the potential Business Combination and the target business&#x2019; attributes, introduce the Company to potential investors that are interested in purchasing its securities in connection with its initial Business Combination and assist with press releases and public filings in connection with the Business Combination. The Company will pay EBC a service fee for such services upon the consummation of its initial Business Combination in an amount equal to 3.5% of the gross proceeds (an aggregate amount of $&lt;span id="xdx_903_ecustom--AggregateAmount_iI_c20260331_zTH308ltPdjd" title="Aggregate amount"&gt;3,500,000&lt;/span&gt;) of the Initial Public Offering. In addition, the Company will pay EBC a service fee in an amount equal to 1.0% of the total consideration payable in the initial Business Combination if it introduces the Company to the target business with whom it completes an initial Business Combination; provided that the foregoing fee will not be paid prior to the date that is 60 days from the effective date of the Initial Public Offering, unless FINRA determines that such payment would not be deemed underwriters&#x2019; compensation in connection with the Initial Public Offering pursuant to FINRA Rule&#160;5110. In accordance with ASC 805-10-25-23, the Company will not recognize any expenses related to the Business Combination Marketing Agreement until and if the Business Combination closes as the Company has not incurred and will not incur any costs related to such services until and if a Business Combination is consummated successfully. Management has determined that the Business Combination Marketing Agreement fees are not payable as of March&#160;31, 2026, and will only record a liability on the date of the Company&#x2019;s initial Business Combination.&lt;/span&gt;&lt;/p&gt;





</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact000676"
      unitRef="Shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-02-19"
      decimals="INF"
      id="Fact000678"
      unitRef="Shares">1500000</us-gaap:SharesIssued>
    <rfa:SharesSubjectToForfeiture
      contextRef="From2026-02-012026-02-19"
      decimals="INF"
      id="Fact000680"
      unitRef="Shares">500000</rfa:SharesSubjectToForfeiture>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="From2025-10-012026-03-31_us-gaap_IPOMember"
      decimals="0"
      id="Fact000681"
      unitRef="USD">2000000</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <rfa:AggregateAmount
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000688"
      unitRef="USD">3500000</rfa:AggregateAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000691">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zY4pSdktzoMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 7 &#x2014; &lt;span id="xdx_828_zKYjMxsv6GO1"&gt;SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Preference Shares&lt;/i&gt;&lt;/b&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_c20260331_zrX3OjrO6D9" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt; preference shares with a par value of $&lt;span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20260331_za7hl0hZ7a2e" title="Preferred stock, par value"&gt;0.0001&lt;/span&gt; per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. As of March&#160;31, 2026 and September&#160;30, 2025, there were &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20260331_ze0dwoPrj8j1" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20260331_zh4wguWDaCf8" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt; preference shares issued or outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Ordinary Shares&lt;/i&gt;&lt;/b&gt; &#x2014; The Company is authorized to issue &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zzC3bz4v7jk8" title="Common stock, shares authorized"&gt;200,000,000&lt;/span&gt; ordinary shares with a par value of $&lt;span id="xdx_90D_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAOrdinarySharesMember_zZJssbcNKdle" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share. Holders of ordinary shares are entitled to one vote for each share. As of March&#160;31, 2026 and September&#160;30, 2025, there were &lt;span id="xdx_90E_eus-gaap--CommonStockSharesIssued_iI_c20260331_z0slkpLYY7Pa" title="Common stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20260331_zK0nb3xyWmx4" title="Common stock, shares outstanding"&gt;3,933,333&lt;/span&gt;&lt;/span&gt; and 3,833,333 ordinary shares issued and outstanding (excluding 10,000,000 and 0 shares subject to possible redemption), respectively. As of September&#160;30, 2025, the issued and outstanding ordinary shares include an aggregate of up to &lt;span id="xdx_90A_ecustom--SharesSubjectToForfeiture_c20251001__20260331_zIRxOFnue43h" title="Shares subject to forfeiture"&gt;500,000&lt;/span&gt; ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised within the 45-day period following the closing of the Initial Public Offering. On February&#160;19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional &lt;span id="xdx_907_eus-gaap--SharesIssued_iI_c20260219_zFXicVcNY8c4" title="Shares issued"&gt;1,500,000&lt;/span&gt; Units, resulting in the forfeiture of the &lt;span id="xdx_906_ecustom--SharesSubjectToForfeiture_c20260201__20260219_zILkyI6ehA99" title="Shares subject to forfeiture"&gt;500,000&lt;/span&gt; Founder Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Rights&lt;/i&gt;&lt;/b&gt; &#x2014; Except in cases where the Company is not the surviving company in a Business Combination, each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of the initial Business Combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one-tenth (1/10) of one ordinary share underlying each right upon consummation of the Business Combination. If the Company is unable to complete the initial Business Combination within the required time period and the Company will redeem the public shares for the funds held in the Trust Account, holders of rights will not receive any of such funds for their rights and the rights will expire worthless.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
























</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000693"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000695"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember"
      decimals="INF"
      id="Fact000701"
      unitRef="Shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassAOrdinarySharesMember"
      decimals="INF"
      id="Fact000703"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000705"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact000707"
      unitRef="Shares">3933333</us-gaap:CommonStockSharesOutstanding>
    <rfa:SharesSubjectToForfeiture
      contextRef="From2025-10-01to2026-03-31"
      decimals="INF"
      id="Fact000709"
      unitRef="Shares">500000</rfa:SharesSubjectToForfeiture>
    <us-gaap:SharesIssued
      contextRef="AsOf2026-02-19"
      decimals="INF"
      id="Fact000711"
      unitRef="Shares">1500000</us-gaap:SharesIssued>
    <rfa:SharesSubjectToForfeiture
      contextRef="From2026-02-012026-02-19"
      decimals="INF"
      id="Fact000713"
      unitRef="Shares">500000</rfa:SharesSubjectToForfeiture>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000720">&lt;p id="xdx_807_eus-gaap--FairValueDisclosuresTextBlock_zTNNtVaeDhHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 8 &#x2014; &lt;span id="xdx_82E_zze1Wlr9pUC1"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3:&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Unobservable inputs based on assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The over-allotment option was accounted for as a liability in accordance with FASB ASC 815-40 upon the closing of the Initial Public Offering. The over-allotment option liability is measured at fair value at inception and on a recurring basis, with changes in fair value presented within changes in fair value of over-allotment option liability in the unaudited condensed statements of operations. On February 19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional 1,500,000 Units, and the Company derecognized the over-allotment liability accordingly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company used a Black-Scholes model to value the over-allotment option. The over-allotment option liability was classified within Level 3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in pricing models are assumptions related to expected share-price volatility, expected life and risk-free interest rate. The Company estimates the volatility of its ordinary shares based on historical volatility that matches the expected remaining life of the option. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the option. The expected life of the option is assumed to be equivalent to their remaining contractual term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The key inputs into the Black-Scholes model were as follows at initial measurement of the over-allotment option:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2hX9sB3k42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B5_zhirNItrbSo3" style="display: none"&gt;Schedule of Black-Scholes model&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;17,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zm3zgDzALFPj" title="Risk-free interest rate"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsbSxXhV32F3" title="Expected term (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBKNOMgt5Z1c" title="Volatility"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePrice_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zayxy5eFLLRj" title="Exercise price"&gt;9.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z1aJJIE83s09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

























&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The over-allotment option was forfeited on
February 19, 2026. As such, the fair value of the over-allotment option was $&lt;span id="xdx_902_ecustom--ChangeOnFairValueOfOverallotmentLiability_c20251001__20260331_zeb4MNtTi5W4" title="Change on fair value of over-allotment liability"&gt;422,000&lt;/span&gt;
and zero at the IPO date and March 31, 2026, respectively. The change in the over-allotment option was $&lt;span id="xdx_908_ecustom--ChangeOnFairValueOfOverallotmentLiability_c20260101__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z4Zp6QnQ8MK1" title="Change on fair value of over-allotment liability"&gt;422,000&lt;/span&gt;
for the three and six months ended March 31, 2026, which is included in change in fair value of over-allotment liability under other
income in the accompanying unaudited statements of operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The fair value of the Public Rights issued in the Initial Public Offering is $2,003,000, or $0.2003 per Public Right. The Public Rights have been classified within shareholders&#x2019; equity and will not require remeasurement after issuance. The Public Rights were classified within Level 3 of the fair value hierarchy at the measurement dates due to the use of unobservable inputs inherent in assumptions related to the market adjustments as noted below. The following table presents the quantitative information regarding market assumptions used in the valuation of the Public Rights:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zC0rl4znf4m" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B2_zBKMuqCl1U4g" style="display: none"&gt;Schedule of market assumptions used in the valuation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;17,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_dtY_c20260201__20260217_zNc6ZMDIOA6f" title="Term (years)"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c20260201__20260217_zt2VSNDJY1f" title="Risk-free rate"&gt;3.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c20260201__20260217_zNdQClINulWf" title="Volatility"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Implied discount for lack of marketability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ImpliedDiscountForLackOfMarketability_c20260201__20260217_zLrBKvkFxEWc" title="Implied discount for lack of marketability"&gt;2.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zSiMq0SyQGTk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="From2025-10-012026-03-31_us-gaap_OverAllotmentOptionMember"
      id="Fact000722">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_hus-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z2hX9sB3k42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B5_zhirNItrbSo3" style="display: none"&gt;Schedule of Black-Scholes model&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;17,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zm3zgDzALFPj" title="Risk-free interest rate"&gt;3.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Expected term (years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zsbSxXhV32F3" title="Expected term (years)"&gt;0.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dtY_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zBKNOMgt5Z1c" title="Volatility"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Exercise price&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_ecustom--ExercisePrice_c20260201__20260217__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zayxy5eFLLRj" title="Exercise price"&gt;9.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2026-02-012026-02-17_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000724"
      unitRef="Ratio">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2026-02-012026-02-17_us-gaap_OverAllotmentOptionMember"
      id="Fact000726">P0Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2026-02-012026-02-17_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000728"
      unitRef="Ratio">8.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <rfa:ExercisePrice
      contextRef="From2026-02-012026-02-17_us-gaap_OverAllotmentOptionMember"
      decimals="INF"
      id="Fact000730"
      unitRef="USDPShares">9.80</rfa:ExercisePrice>
    <rfa:ChangeOnFairValueOfOverallotmentLiability
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000737"
      unitRef="USD">422000</rfa:ChangeOnFairValueOfOverallotmentLiability>
    <rfa:ChangeOnFairValueOfOverallotmentLiability
      contextRef="From2026-01-012026-03-31_us-gaap_OverAllotmentOptionMember"
      decimals="0"
      id="Fact000739"
      unitRef="USD">422000</rfa:ChangeOnFairValueOfOverallotmentLiability>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000741">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zC0rl4znf4m" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FAIR VALUE MEASUREMENTS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B2_zBKMuqCl1U4g" style="display: none"&gt;Schedule of market assumptions used in the valuation&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: bottom; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;February&#160;17,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"&gt;Term (years)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1_dtY_c20260201__20260217_zNc6ZMDIOA6f" title="Term (years)"&gt;1.75&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Risk-free rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c20260201__20260217_zt2VSNDJY1f" title="Risk-free rate"&gt;3.44&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c20260201__20260217_zNdQClINulWf" title="Volatility"&gt;8.8&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Implied discount for lack of marketability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ImpliedDiscountForLackOfMarketability_c20260201__20260217_zLrBKvkFxEWc" title="Implied discount for lack of marketability"&gt;2.7&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <rfa:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1 contextRef="From2026-02-012026-02-17" id="Fact000743">P1Y9M</rfa:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000745"
      unitRef="Ratio">3.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000747"
      unitRef="Ratio">8.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <rfa:ImpliedDiscountForLackOfMarketability
      contextRef="From2026-02-012026-02-17"
      decimals="INF"
      id="Fact000749"
      unitRef="Ratio">2.7</rfa:ImpliedDiscountForLackOfMarketability>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000751">&lt;p id="xdx_809_eus-gaap--SegmentReportingDisclosureTextBlock_zK0AgawuOUNa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 9 &#x2014; &lt;span id="xdx_82B_zHdnsH9DU0L9"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB ASC Topic 280, &#x201c;Segment Reporting,&#x201d; establishes standards for companies to report in their financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise that engage in business activities from which it may recognize revenues and incur expenses, and for which separate financial information is available that is regularly evaluated by the Company&#x2019;s CODM, or group, in deciding how to allocate resources and assess performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s CODM has been identified as the Chief Executive Officer, who reviews the assets, operating results, and financial metrics for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one reportable segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the unaudited condensed statement of operations as net income or loss. When evaluating the Company&#x2019;s performance and making key decisions regarding resource allocation, the CODM reviews several key metrics, which include profit or loss comprised of general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zcdwOQzkAsu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvAqf6MW1swb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20260331_zHdcEHF6t93b" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250930_z4UEMpqOknw3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Cash_iI_ztjA46hs7Y99" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top"&gt;Cash&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;933,390&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsHeldInTrust_iI_zk7nx2PcgcFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;100,403,232&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_497_20260101__20260331_z8uTibPhVzJ5" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_490_20251001__20260331_z2mX6oWyxqLj" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; three months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the&lt;br/&gt; six months ended&lt;br/&gt; March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherGeneralAndAdministrativeExpense_zn1YthQcpU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;General and administrative costs&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;99,246&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;152,199&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InterestIncomeExpenseNet_zpIYRbfHhZ02" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Interest earned on cash held in Trust Account&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;403,232&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;403,232&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A4_zvqHIwRWfzC6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The key measures of segment profit or loss reviewed by the CODM are general and administrative costs. General and administrative costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a Business Combination within the Combination period. The CODM also reviews general and administrative costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;





















</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000753">&lt;table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zcdwOQzkAsu5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT INFORMATION (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&lt;span id="xdx_8B8_zvAqf6MW1swb" style="display: none"&gt;Schedule of segment information&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_495_20260331_zHdcEHF6t93b" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20250930_z4UEMpqOknw3" style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;br/&gt; 2026&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September&#160;30,&lt;br/&gt; 2025&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Cash_iI_ztjA46hs7Y99" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top"&gt;Cash&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;933,390&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0756"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AssetsHeldInTrust_iI_zk7nx2PcgcFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Cash held in Trust Account&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;100,403,232&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0759"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Cash
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000755"
      unitRef="USD">933390</us-gaap:Cash>
    <us-gaap:AssetsHeldInTrust
      contextRef="AsOf2026-03-31"
      decimals="0"
      id="Fact000758"
      unitRef="USD">100403232</us-gaap:AssetsHeldInTrust>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000761"
      unitRef="USD">99246</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000762"
      unitRef="USD">152199</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2026-01-012026-03-31"
      decimals="0"
      id="Fact000764"
      unitRef="USD">403232</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2025-10-01to2026-03-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">403232</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-10-01to2026-03-31" id="Fact000772">&lt;p id="xdx_804_eus-gaap--SubsequentEventsTextBlock_zuNbM4UFjsQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE 10 &#x2014; &lt;span id="xdx_82C_z8i2zP9hLLE7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date and through the date that the unaudited condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-10-01to2026-03-31" id="Fact000773">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-10-01to2026-03-31" id="Fact000774">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-10-01to2026-03-31" id="Fact000775">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-10-01to2026-03-31" id="Fact000776">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000130"
          xlink:label="Fact000130"
          xlink:type="locator"/>
        <link:footnote id="Footnote000160" xlink:label="Footnote000160" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 3,833,333 Founder Shares as of September&#160;30, 2025 includes up to 500,000 ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On February&#160;19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional 1,500,000 Units, resulting in the forfeiture of the 500,000 Founder Shares (Note 5).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000130"
          xlink:to="Footnote000160"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000131"
          xlink:label="Fact000131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000131"
          xlink:to="Footnote000160"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000191"
          xlink:label="Fact000191"
          xlink:type="locator"/>
        <link:footnote id="Footnote000208" xlink:label="Footnote000208" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 3,833,333 Founder Shares as of September 30, 2025 includes up to 500,000 ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On February&#160;19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional 1,500,000 Units, resulting in the forfeiture of the 500,000 Founder Shares (Note 5).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000191"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000193"
          xlink:label="Fact000193"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000193"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000195"
          xlink:label="Fact000195"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000195"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000197"
          xlink:label="Fact000197"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000197"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000199"
          xlink:label="Fact000199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000199"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000201"
          xlink:label="Fact000201"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000201"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000203"
          xlink:label="Fact000203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000203"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000205"
          xlink:label="Fact000205"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000205"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000206"
          xlink:label="Fact000206"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000206"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000207"
          xlink:label="Fact000207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000207"
          xlink:to="Footnote000208"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000215"
          xlink:label="Fact000215"
          xlink:type="locator"/>
        <link:footnote id="Footnote000283" xlink:label="Footnote000283" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The 3,833,333 Founder Shares as of September 30, 2025 includes up to 500,000 ordinary shares subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters. On February 19, 2026, the underwriters elected to forfeit their over-allotment option to purchase up to an additional 1,500,000 Units, resulting in the subsequent forfeiture of the 500,000 Founder Shares (Note 5).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000215"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000222"
          xlink:label="Fact000222"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000222"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000234"
          xlink:label="Fact000234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000234"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000248"
          xlink:label="Fact000248"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000248"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000270"
          xlink:label="Fact000270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000270"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000282"
          xlink:label="Fact000282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000282"
          xlink:to="Footnote000283"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>